<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195805</url>
  </required_header>
  <id_info>
    <org_study_id>MED.RES.HOS.2010.03.SKM</org_study_id>
    <nct_id>NCT01195805</nct_id>
  </id_info>
  <brief_title>The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables</brief_title>
  <acronym>hass</acronym>
  <official_title>The Effect of Amiloride and Spironolactone on Renovascular and Cardiovascular Variables in Patients With Essential Hypertension in a Doubleblinded, Randomized, Placebo-controlled, Crossover Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators wish to study the effect of retaining potassium. The participants have
      essential hypertension. The test substances are Amiloride, Spironolactone and placebo. The
      participants will ingest tablets for 28 days before being examined. We will perform a 24
      hours urine collection, 24-hours bloodpressure measurement, blood and urine samples and we
      also examine the patient using a SphygmoCor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose of the study is to examine the effect of amiloride and spironolactone on

        1. Renal function (GFR, u-AQP2, u-ENaCÎ², u-cAMP, u-PGE2, CH20, FENa, FEK),

        2. Pulsewave velocity, augmentation index central bloodpressure,

        3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and

        4. Ambulatory bloodpressure
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bloodpressure</measure>
    <time_frame>24-hours and examination</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Amiloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet twice a day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>1 tablet twice a day for 28 days</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet twice a day for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>1 tablet twice a day for 28 days</description>
    <arm_group_label>Amiloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypertension,

          -  BMI 18,5-30,

          -  non-smoker

        Exclusion Criteria:

          -  Smoking

          -  Not using contraceptives

          -  Other illnesses

          -  Drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solveig K Matthesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departments of medical research and medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departments of medical research and medicine</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Blood pressure, PWV, HRV, PWV, potassium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

